N-(2-aminoethyl)-3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanamide | 1187651-71-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(2-aminoethyl)-3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanamide
• 英文别名: N-(2-Amino-ethyl)-3-[4-(2-hydroxy-3-isopropylamino-propoxy)-phenyl]-propionamide；N-(2-aminoethyl)-3-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]propanamide
• CAS: 1187651-71-3
• 化学式: C₁₇H₂₉N₃O₃
• 分子量: 323.436
• InChiKey: QHHQYHWQMNLAMW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  23
• 可旋转键数：
  11
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  96.6
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(2-aminoethyl)-3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanamide 在 盐酸 作用下， 以 甲醇 、 异丙醇 为溶剂， 以48.4%的产率得到N-(2-aminoethyl)-3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanamide dihydrochloride
  参考文献：
  名称：

  Synthesis andIn VivoEvaluation of a Kit-Type^99mTc-labeledN-(2-Aminoethyl)-3-(4-(2-hydroxy-3-(isopropylaminopropoxy)phenyl)propanamide as a Selective β₁-Adrenoceptor-binding SPECT Radiotracer

  摘要：

  To develop a novel β1‐adrenoceptor selective radiotracer, 99mTc‐labeld N‐(2‐aminoethyl)‐3‐(4‐(2‐hydroxy‐3‐(isopropylaminopropoxy)phenyl)propanamide ([ 99mTc]1) was prepared by incorporating [ 99mTcO4 ]− into the precursor 3. Radiotracer [ 99mTc]1 was optimized in several reaction conditions for kit‐type preparation of 99mTc‐radiopharmaceuticals. The radiochemical yield was around 95% (non‐decay corrected) within 30 s labeling time and radiochemical purity showed over 98%. In image studies, [ 99mTc]1 provided a good heart accumulation, whereas liver and lung uptakes showed relatively low at initial time. Furthermore, [ 99mTc]1 images at 25 min post‐injection provided a clearly visible cardiac image with high contrast. To confirm the β1‐adrenoceptor‐binding specificity of [ 99mTc]1, a blocking experiment was performed. In vivo blocking with excess esmolol (18 mg/kg) or atenolol (2 mg/kg) resulted in significantly reduced radioactivity uptake in the heart around 92 and 76%, respectively. The results suggested that [ 99mTc]1 might be of worth applying to the assessment of β1‐adrenoceptor expression in the heart diseases.

  DOI：

  10.1002/bkcs.11027
• 作为产物：
  描述：

  艾司洛尔 、 乙二胺 以 甲醇 为溶剂， 反应 8.0h， 以74%的产率得到N-(2-aminoethyl)-3-(4-(2-hydroxy-3-(isopropylamino)propoxy)phenyl)propanamide
  参考文献：
  名称：

  IMAGE-GUIDED THERAPY OF MYOCARDIAL DISEASE: COMPOSITION, MANUFACTURING AND APPLICATIONS

  摘要：

  揭示了用于成像、化疗和放疗的构成物和方法。更具体地，本发明涉及含有靶向单元的试剂，该靶向单元包括与乙二胺共轭或嵌入的β-肾上腺素受体靶向化合物。本发明还涉及应用这种试剂进行心血管疾病成像和治疗的方法，以及用于制备放射标记治疗或诊断试剂的试剂盒。

  公开号：

  US20090238756A1

文献信息

• Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure
  申请人：Taylor George Malcolm

  公开号：US20080090827A1

  公开（公告）日：2008-04-17

  This invention provides compounds that possess inhibitory activity against β-adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against β-adrenergic receptors and PDE.

  本发明提供了具有抑制β-肾上腺素能受体和磷酸二酯酶PDE（包括磷酸二酯酶3（PDE3））活性的化合物。本发明还提供了包含这些化合物的药物组合物；使用这些化合物治疗心血管疾病、中风、癫痫、眼科疾病或偏头痛的方法；以及制备具有抑制β-肾上腺素能受体和PDE活性的药物组合物和化合物的方法。
• COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
  申请人：Artesian Therapeutics, Inc.

  公开号：EP1830852A2

  公开（公告）日：2007-09-12
• IMAGE-GUIDED THERAPY OF MYOCARDIAL DISEASE: COMPOSITION, MANUFACTURING AND APPLICATIONS
  申请人：THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20130302245A1

  公开（公告）日：2013-11-14

  Compositions and methods for imaging and for chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns agents comprising a targeting moeity comprising a beta-adrenergic receptor targeting compound conjugated or embedded with ethylenediamine. The present invention also concerns methods of application of such agents for imaging and treatment of cardiovascular diseases, and kits for preparing a radiolabeled therapeutic or diagnostic agent.
• US8440168B2
  申请人：——

  公开号：US8440168B2

  公开（公告）日：2013-05-14
• [EN] COMPOUNDS WITH MIXED PDE-INHIBITORY AND ß-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE<br/>[FR] COMPOSES A ACTIVITE A LA FOIS INHIBITRICE DE LA PDE ET ANTAGONISTE OU AGONISTE PARTIELLE DES RECEPTEURS $G(B)-ADRENERGIQUES POUR LE TRAITEMENT DE L'INSUFFISANCE CARDIAQUE
  申请人：ARTESIAN THERAPEUTICS INC

  公开号：WO2006060127A2

  公开（公告）日：2006-06-08

  [EN] This invention provides compounds that possess inhibitory activity against ß-adrenergic receptors and phosphodiesterases, including phosphodiesterase 3 (PDE3). This invention further provides pharmaceutical compositions comprising such compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ß-adrenergic receptors and PDE.
  [FR] Cette invention concerne des composés qui présentent une activité inhibitrice contre des récepteurs ß-adrénergiques et des phosphodiestérases, y compris la phosphodiestérase 3 (PDE3). Cette invention concerne également des compositions pharmaceutiques renfermant ces composés, des procédés utilisant ces composés pour traiter une maladie cardiovasculaire, un accident vasculaire cérébral, l'épilepsie, un trouble ophtalmique ou la migraine, ainsi que des procédés de préparation de compositions pharmaceutiques et de composés qui présentent une activité inhibitrice contre des récepteurs ß-adrénergiques et la PDE.